Adam Spivak, MD
Adam Spivak, MD, is an emerging investigator and faculty member in the Division of Infectious Diseases at the University of Utah. Dr. Spivak is a provider in Clinic 1A at the University of Utah Medical Center where he cares for patients with HIV infection.
During infectious diseases fellowship Dr. Spivak led a multi-center pilot clinical trial administering the FDA-approved drug disulfiram to HIV patients on ART to evaluate the effect on the HIV latent reservoir in resting T cells. He currently spends the majority of his time engaged in bench-based translational research focused on HIV persistence and eradication.
Noah Kolb, MD
Noah Kolb, MD's, primary research interest is in neuropathy. He is the site investigator for the IGOS (International Guillian Barre Outcome Study). This study examines the natural history of Guillian Barre in an effort to identify potential biomarkers for prognosis. Currently he is working on several projects to examine risk factors, patient reported outcomes measures, and tools for the diagnosis of chemotherapy induced neuropathy, one of the most common and debilitating side effects of life saving cancer treatments.
He recently hosted an international Facebook chat for the Neuropathy Association to inform patients about auto-immune neuropathies and serves on the Podcast Editorial Board for the American Association of Neuromuscular and Electrodiagnostic Medicine
Contact: Rebekah Hendon
Email: Rebekah.Hendon@utah.edu